AndroGel What to Expect: Week-by-Week First Month Guide

What Is AndroGel and Who Uses It?

AndroGel is a hydroalcoholic testosterone gel approved by the FDA for testosterone replacement in men with hypogonadism confirmed by two morning serum testosterone measurements below 300 ng/dL. It is available in two concentrations: 1% (delivering 25 mg or 50 mg per unit dose packet) and 1.62% (delivering 20.25 mg to 81 mg via a metered-dose pump). The FDA label, accessible via FDA accessdata, specifies that diagnosis requires both low serum T and clinical symptoms.

Who Qualifies for a Prescription?

The Endocrine Society's 2018 clinical practice guideline defines biochemical hypogonadism as a total testosterone consistently below 300 ng/dL on two morning samples, combined with symptoms such as reduced libido, fatigue, or decreased morning erections. The guideline, published in the Journal of Clinical Endocrinology and Metabolism, recommends against empirical therapy without confirmed low levels.

How the Gel Works

Once applied to clean, dry skin on the upper arms, shoulders, or abdomen (site varies by product version), testosterone is absorbed through the stratum corneum into the dermal capillaries. Bioavailability from skin ranges from 9% to 14% of the applied dose. Serum levels begin rising within 4 hours of the first application and reach a steady-state plateau after approximately 24 to 72 hours of daily dosing, according to pharmacokinetic data in the AndroGel 1.62% prescribing information.

Week 1: The Pharmacokinetic Foundation

During the first seven days, the primary story is pharmacokinetic, not symptomatic. Serum testosterone rises toward the normal range, but the body has not yet had time to respond at the tissue level.

What the Labs Show in Week 1

After a single application of AndroGel 1.62% at the 40.5 mg starting dose, the mean peak serum testosterone (C-max) in the phase 3 trial reached approximately 553 ng/dL, with a trough (C-min) around 350 ng/dL before the next daily application. These data come from the multicenter, open-label study supporting the 1.62% formulation, summarized in PubMed. Steady-state is not achieved on a single dose; trough levels continue to rise slightly across the first 14 days until absorption and clearance balance out.

Physical Sensations in Week 1

Most men report little to no noticeable change during week 1. A mild increase in skin warmth at the application site, or a slight shift in sleep quality (either direction), is possible. These are early hormonal fluctuations, not side effects requiring action. The FDA label notes that application-site reactions such as acne, dryness, or mild irritation appear in roughly 4% of patients.

Practical Steps in Week 1

Apply the gel at the same time each day, ideally in the morning after a shower. Allow 5 minutes of drying time, then cover the site with clothing to reduce transfer risk. Wash hands immediately with soap and water. The FDA issued a black-box warning in 2009 specifically addressing secondary exposure in children; the full warning text appears in the accessdata label.

Week 2: Mood and Energy Begin to Shift

By day 10 to 14, serum testosterone has typically stabilized near its steady-state range at the starting dose. This is when the first subjective changes tend to emerge.

Energy and Cognitive Effects

The androgen receptor in skeletal muscle and the CNS begins responding once testosterone remains consistently elevated. Men often describe a reduction in afternoon fatigue, clearer thinking, and a greater willingness to initiate physical activity. A 2016 analysis of the T-Trials (N=790 men, aged 65 and older, baseline T below 275 ng/dL) published in the New England Journal of Medicine found that testosterone treatment raised mean serum T to approximately 500 ng/dL and produced statistically significant improvements in sexual activity, physical performance, and self-reported vitality compared with placebo at 12 months. The energy signal appears early in clinical practice, though the T-Trials did not isolate the week-2 window specifically.

Mood Stabilization

Low testosterone is associated with elevated rates of depressive symptoms. A meta-analysis of 27 randomized controlled trials (N=1,890) published in JAMA Psychiatry found that testosterone treatment produced a significant reduction in depressive symptoms compared with placebo (standardized mean difference: 0.21, 95% CI 0.10 to 0.32, P<0.001). Week 2 is when this mood floor often begins to lift.

Week 2 Lab Check: Is It Needed?

No mandatory lab check is required at exactly day 14 unless a dose change was made at initiation. The FDA prescribing information instructs clinicians to check serum testosterone 14 days after any dose adjustment. If this is day 14 since the very first application, some providers draw an early trough T to confirm the patient is within the 400 to 700 ng/dL mid-normal range. Below 400 ng/dL may prompt an uptitration to 60.75 mg (three pump actuations); above 700 ng/dL may indicate a need to reduce.

Week 3: Libido and Morning Erections

Sexual symptoms are among the most common complaints driving men to seek TRT, and they are also some of the earliest to respond once testosterone is consistently in the normal range.

Libido Response Timeline

In the sexual function sub-trial of the T-Trials (N=470), men receiving testosterone gel showed a significantly greater increase in sexual desire scores at 3 months versus placebo, with a mean difference of 2.93 points on the Psychosexual Daily Questionnaire (P<0.001), as reported in NEJM. In clinical practice, the first hints of libido improvement often appear at weeks 3 to 4, not months 3 to 4, because serum T has already normalized by this point.

Morning Erections

Return of spontaneous morning erections is a commonly reported early marker of androgen receptor activity. This happens in the 3-to-4-week window for many patients. Men with significant erectile dysfunction caused by vascular disease or other factors may not see resolution of ED from testosterone alone; the Endocrine Society guideline (JCEM, 2018) notes that phosphodiesterase-5 inhibitors may be needed alongside TRT in those cases.

Erythrocytosis Risk Begins

By week 3, hematocrit begins to rise. Testosterone stimulates erythropoietin production. The Endocrine Society guideline recommends checking hematocrit at baseline, then at 3 to 6 months, and annually thereafter. If hematocrit exceeds 54%, the guideline advises dose reduction or treatment interruption. Monitoring this early matters because erythrocytosis is the most common laboratory adverse effect of TRT, occurring in roughly 5.7% of men on transdermal therapy in a large registry study published in JAMA.

Week 4: Taking Stock at One Month

Week 4 is the first meaningful clinical checkpoint. Steady-state pharmacokinetics are established, early receptor-level effects have begun, and this is the right time for a structured review with your prescribing clinician.

What Should Be Better by Week 4

Energy, mood, and libido are the three domains most likely to show measurable change within 30 days. A prospective study (N=122) published in The Journal of Sexual Medicine found that improvements in sexual desire and overall well-being were detectable within 3 to 4 weeks in eugonadal-range responders. Men whose serum T remains below 350 ng/dL at trough are less likely to report these early benefits.

What May Take Longer

Body composition changes require more time. A randomized trial of testosterone therapy in 209 hypogonadal men, published in the Journal of Clinical Endocrinology and Metabolism, found statistically significant increases in lean mass and decreases in fat mass at 6 months, not at 1 month. Bone mineral density changes are even slower, typically requiring 12 months of consistent therapy to detect by DEXA scan, as discussed in a Cochrane review of testosterone therapy in men.

The Month-1 Lab Panel

At 4 weeks, a reasonable minimum lab panel includes:

• Total testosterone (trough, drawn before the morning application)
• Free testosterone (if total T is in range but symptoms persist)
• Hematocrit and hemoglobin
• PSA (if not drawn at baseline, or as a repeat if baseline was borderline)
• Estradiol (if gynecomastia, fluid retention, or mood swings are present)

The Endocrine Society guideline specifies that PSA should be drawn at 3 to 6 months, then annually in men at normal prostate-cancer risk. Some clinicians draw it at 4 weeks as a practical baseline comparison point.

Dose Adjustments After Month 1

If week-4 trough testosterone falls outside the 400 to 700 ng/dL target range, dose adjustment is indicated according to the FDA 1.62% label.

Uptitration Protocol

• Trough T below 400 ng/dL: increase from 40.5 mg to 60.75 mg (three pump actuations)
• Recheck trough T 14 days later
• Maximum approved dose: 81 mg per day (four pump actuations)

Downtitration Protocol

• Trough T above 750 ng/dL: decrease dose by one pump actuation
• Trough T consistently above 700 ng/dL with symptoms of excess (acne, irritability, erythrocytosis): reduce and recheck in 14 days

A pharmacokinetic modeling study published in Clinical Pharmacokinetics demonstrated that inter-individual variability in transdermal testosterone absorption is substantial (coefficient of variation approximately 40%), which explains why two men at the same starting dose may land at very different trough T values. This variability is the primary reason dose titration cannot be skipped.

Transfer Risk and Application Best Practices

The FDA black-box warning on all testosterone gel products addresses the risk of secondary exposure. Testosterone virilizes children and causes menstrual irregularities and clitoromegaly in women. Documented cases of virilization in children from skin-to-skin contact led to the labeling update in 2009, described in the FDA Drug Safety Communication.

Minimizing Transfer

• Apply to upper arms or shoulders (not areas likely to contact others)
• Allow 5 minutes of air-drying before covering with clothing
• Wash hands immediately
• Shower before close skin contact if less than 6 hours have elapsed since application

Skin Conditions That Reduce Absorption

Broken skin, heavy body hair at the application site, and topical moisturizer applied before the gel can each reduce absorption by an estimated 20% to 30%, based on pharmacokinetic sub-analyses in the AndroGel product labeling. Apply to clean, dry skin only.

Managing Side Effects in the First Month

Acne and Oily Skin

Sebaceous gland activity increases with androgen stimulation. Mild facial or back acne appears in roughly 4% to 6% of men starting TRT, based on adverse event rates in the AndroGel 1.62% phase 3 trial. Gentle twice-daily cleansing with a salicylic acid wash is a reasonable first step. Persistent acne warrants a dermatology referral before attributing it solely to testosterone.

Fluid Retention

Testosterone promotes mild sodium and water retention through aldosterone pathway interactions. Ankle edema appearing in the first 2 to 4 weeks is reported in approximately 2% to 3% of patients. Men with pre-existing heart failure, hepatic cirrhosis, or chronic kidney disease carry a higher risk; the Endocrine Society guideline lists these as conditions requiring careful monitoring or contraindication assessment before initiating therapy.

Gynecomastia

Peripheral aromatization converts testosterone to estradiol. If estradiol rises disproportionately, breast tissue proliferation may follow. Gynecomastia significant enough to require intervention appears in fewer than 1% of men on transdermal TRT in the first month, but patients should report breast tenderness early. An estradiol level drawn at the 4-week visit guides whether an aromatase inhibitor is appropriate; off-label use of anastrozole 0.5 mg twice weekly is common in clinical practice, though not FDA-approved for this indication.

What the T-Trials Tell Us About Realistic Expectations

The T-Trials, a coordinated set of seven double-blind, placebo-controlled trials conducted at 12 U.S. Sites (N=790 men, age 65 or older, baseline T below 275 ng/dL), provide the most rigorous modern data on testosterone gel outcomes across multiple domains. Results were published collectively in the New England Journal of Medicine in 2016.

Key findings across the first 12 months:

• Sexual function trial: testosterone improved sexual desire, erectile function, and sexual activity scores significantly versus placebo (P<0.001 for sexual desire domain).
• Physical function trial: a modest but statistically significant improvement in 6-minute walk distance (average 12.6 meters, P=0.02).
• Vitality trial: no statistically significant improvement in fatigue scores on the Functional Assessment of Chronic Illness Therapy-Fatigue scale versus placebo (P=0.07), a finding that tempers claims about universal energy improvement.
• Bone density trial: testosterone significantly increased volumetric bone mineral density at 12 months (P<0.001).
• Anemia trial: testosterone corrected unexplained anemia in 58% of treated men versus 22% placebo (P<0.001).

The vitality finding deserves emphasis. The T-Trials did not confirm a significant fatigue benefit in men aged 65 and older as a group. Younger men with more profound hypogonadism may still experience meaningful energy gains, but the T-Trials data caution against overpromising on this endpoint universally.

As the T-Trials investigators wrote: "The results demonstrate that testosterone treatment of older men with low testosterone levels produced significant benefits in sexual function" while noting that benefits in vitality and physical function were smaller or marginal. This framing from the primary publication sets realistic expectations for clinicians and patients alike.

Special Populations and Considerations

Men Over 65

The T-Trials population (mean age 72) had a higher baseline cardiovascular risk profile than typical TRT candidates. The American Heart Association has called for additional long-term cardiovascular safety data. The TRAVERSE trial (N=5,246, mean age 57), published in the New England Journal of Medicine in 2023, found no significant increase in major adverse cardiovascular events with testosterone therapy versus placebo over a mean follow-up of 33 months in men with hypogonadism and elevated cardiovascular risk.

Men Desiring Fertility Preservation

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH, which in turn suppresses spermatogenesis. Men who want to preserve fertility should not use AndroGel. The American Society for Reproductive Medicine explicitly advises against exogenous testosterone in men who wish to father children, recommending clomiphene citrate or gonadotropin therapy instead.

Diabetes and Metabolic Syndrome

A meta-analysis published in Diabetes Care (N=857 men across 8 trials) found that testosterone therapy reduced fasting glucose, insulin resistance (HOMA-IR), and waist circumference in men with metabolic syndrome or type 2 diabetes compared with placebo. The effect on HbA1c was modest but directionally favorable. These men may see metabolic benefits alongside the symptomatic ones, though glycemic monitoring should continue unchanged in the first month.

Week-by-Week Summary Table

| Week | Primary Changes | Labs / Actions | |------|----------------|----------------| | 1 | Serum T rising toward steady-state; few subjective changes | None required unless dose adjustment made | | 2 | Energy and mood begin to shift; trough T stabilizing | Optional early trough T draw; confirm technique | | 3 | Libido and morning erections may return; hematocrit climbing | Watch for application-site reactions | | 4 | First full clinical checkpoint | Trough T, hematocrit, PSA (if indicated), estradiol |